GammaTile®(GT)作为快速增殖性胶质母细胞瘤的近距离放疗平台:从病例系列到临床试验
本研究前瞻性随访7例快速增殖性IDH野生型胶质母细胞瘤患者(新诊断3例、复发4例),均接受再切除后GammaTile®(GT)植入。中位随访347天,新诊断与复发患者的中位无进展生存期均≥320天,中位总生存期分别为347天和304天。作者认为GT局部控制良好且安全性可接受,为未来临床试验设计奠定基础。
要点
- 7例快速增殖性IDH野生型胶质母细胞瘤患者接受再切除后GT植入,无手术并发症。
- 中位随访347天,新诊断与复发患者中位无进展生存期均≥320天。
- 中位总生存期新诊断患者347天、复发患者304天,无30天死亡。
核心结论
- 作者初步经验提示,GT对快速增殖性胶质母细胞瘤患者提供有利的局部控制和安全性,并为未来临床试验设计奠定基础。
研究设计与样本
- 前瞻性随访7例连续患者(2019—2023年),均为新诊断(n=3)或复发(n=4)的异柠檬酸脱氢酶野生型胶质母细胞瘤,且在初始诊断/手术至放疗计划MRI之间的30天内体积增长>100%。
- 患者接受再切除后行GT植入。
主要发现
- 无手术并发症;1例患者在再切除/GT植入前出现右侧偏瘫并转至康复机构,其余患者均出院回家,中位住院时间为2天(范围:1—5天)。
- 无30天死亡,1例30天再入院(脑积水,需脑室腹腔分流(14%))。
- 中位随访347天(11.6个月),新诊断和复发胶质母细胞瘤患者的中位无进展生存期均≥320天(10.6个月)。
- 复发和 new diagnosed 胶质母细胞瘤患者的中位总生存期分别为304天和347天(10个月和11.5个月)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation plays a central role in glioblastoma treatment. Logistics related to coordinating clinic visits, radiation planning, and surgical recovery necessitate delay in radiation delivery from the time of diagnosis. Unimpeded tumor growth occurs during this period, and is associated with poor clinical outcome. Here we provide a pilot experience of GammaTile ® (GT), a collagen tile-embedded Cesium-131 (131Cs) brachytherapy platform for such aggressive tumors. METHODS: We prospectively followed seven consecutive patients (2019-2023) with newly diagnosed (n = 3) or recurrent (n = 4) isocitrate dehydrogenase wild-type glioblastoma that grew > 100% in volume during the 30 days between the time of initial diagnosis/surgery and the radiation planning MRI. These patients underwent re-resection followed by GT placement. RESULTS: There were no surgical complications. One patient developed right hemiparesis prior to re-resection/GT placement and was discharged to rehabilitation, all others were discharged home-with a median hospital stay of 2 days (range: 1-5 days). There was no 30-day mortality and one 30-day readmission (hydrocephalus, requiring ventriculoperitoneal shunting (14%)). With a median follow-up of 347 days (11.6 months), median progression free survival of ≥ 320 days (10.6 months) was achieved for both newly and recurrent glioblastoma patients. The median overall survival (mOS) was 304 and 347 days (10 and 11.5 mo) for recurrent and newly diagnosed glioblastoma patients, respectively. CONCLUSION: Our pilot experience suggests that GT offers favorable local control and safety profile for patients afflicted with rapidly proliferating glioblastomas and lay the foundation for future clinical trial design.
引用
- Yekula A, Gessler DJ, Ferreira C, et al. GammaTile® (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials. J Neurooncol. 2024. PMID: 38281303. doi:10.1007/s11060-023-04545-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。